The Latest Breaking News from CI

With the rise of chronic diseases, technological advances and innovative drug pipelines are driving significant growth in the healthcare industry. Hence, investors may find long-term stability and exciting opportunities by adding stocks, Johnson & Johnson (JNJ), Pfizer (PFE), and Cigna Group (CI), to their portfolios. Read more….

Cigna Group is set to announce its fiscal third-quarter earnings next week, and analysts anticipate a modest single-digit profit increase.

The healthcare sector is set for robust growth, driven by surging demand for quality treatments, a growing patient base, breakthroughs in biopharma, and supportive policies. Therefore, investors could consider undervalued pharmaceutical stocks like Merck & Co. (MRK), Pfizer (PFE), and Cigna (CI) with significant upside potential. Read more.

The Cigna Group has outperformed the Nasdaq Composite over the past year and analysts remain bullish about the stock’s prospects.

The billionaire explains his view on the future of affordable medicine.

Blue-chip stocks offer stability and consistent growth irrespective of market conditions. Thus, blue chip names Lockheed Martin (LMT), Regeneron Pharmaceuticals (REGN), and Cigna Group (CI) could be prudent additions to your portfolios. These stocks are Strong Buy-rated in our proprietary POWR Ratings system. Read on.

Cigna Group has underperformed the broader market over the past year, but Wall Street analysts are optimistic about the stock’s prospects.

Here’s a dividend-paying gem trading at an attractive valuation, which investors can consider this July while it's still a bargain.

Cigna Group is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit increase.